SAN ANTONIO, Feb. 1 Obagi Medical Products, Inc.(Nasdaq: OMPI), a leader in topical aesthetic and therapeutic skin healthsystems, announced the results of four studies of the CLENZIderm M.D.(TM) AcneTherapeutic Systems' two proprietary 3-step acne treatments, today at the 66thAnnual Meeting of the American Academy of Dermatology in San Antonio. Thedata show that patients of all skin types with mild-to-moderately severe acnesaw significant improvement in inflammatory and non-inflammatory lesions andreported high levels of patient satisfaction, lower levels of dryness andgreater comfort when using the innovative formulation of solubilized 5%benzoyl peroxide (BPO) in the CLENZIderm M.D.(TM) Systems.
"The data show that CLENZIderm M.D. System is not only effective intreating acne, but also well tolerated by all skin types, which is often areason patients cite for non-compliance with other acne treatments," saidJames Leyden, MD, University of Pennsylvania Health Systems and KGL, Inc., andlead investigator of the study comparing facial tolerability of the 3-stepacne system to the BPO/clindamycin combination product on normal-to-dry skin."The solubilized BPO in both the gel and lotion forms is a significantadvancement in benzoyl peroxide technology, enhancing delivery to the targetsite of acne therapy without the excessive drying, flaking and peeling thatmay occur with other treatments."
The Obagi Medical Products 3-step acne system, branded CLENZIderm M.D.Systems, contain 5% solubilized BPO which helps aid in the follicularpenetration of BPO. Traditional BPO formulations are poorly soluble, existingprimarily as macrocrystals, some of which are too large to enter the folliclesand treat acne issues at their source.
"With the solubilized BPO in the CLENZIderm M.D. Systems, we have beenable to improve upon the treatment of acne," said Steven Carlson, ChiefExecutive Officer of Obagi Medical Products. "By offering a product thatpenetrates the pores and reduces acne flare-ups quickly and effectively,without the need for antibiotics, Obagi is at the forefront of dermatologicaladvancements."
About the CLENZIderm M.D. Systems
The CLENZIderm M.D. System, which uses proprietary ingredients, has twoformulations based on skin type. The CLENZIderm System for normal-to-oily skinincludes salicylic acid cleanser, toner and the 5% solubilized BPO gel. TheCLENZIderm M.D. System for normal-to-dry skin includes a gentle creamcleanser, a therapeutic lotion containing solubilized 5% BPO and a therapeuticmoisturizer with 20% glycerin.
Use of benzoyl peroxide-containing products, including CLENZIderm M.D.Serum Gel and Therapeutic Lotion can cause transient stinging and burning insome patients. However, in clinical trials, this transient stinging andburning did not affect patient satisfaction and continued compliance. Sideeffects tend to subside within two weeks of use.
About Obagi Medical Products, Inc.
Obagi Medical Products develops and commercializes skin health productsfor the dermatology, plastic surgery, and related aesthetic markets. Using itsPenetrating Therapeutics(TM) technologies, Obagi Medical's products aredesigned to improve penetration of agents across the skin barrier for commonand visible skin conditions in adult skin including chloasma, melasma, senilelentigines, acne vulgaris and sun damage. The history of Obagi's skin careproduct introductions is as follows: Obagi Nu-Derm(TM), 1988; Obagi-C Rx(TM)(the first and only prescription-strength vitamin C and hydroquinone system),2004; Obagi Professional-C(TM) (a line of highly stable vitamin C serums),2005; Obagi Nu-Derm(TM) Condition and Enhance for use with cosmetic proceduresto enhance patient outcomes and satisfaction, 2006; Obagi ELASTIderm(TM) eyetreatment and Obagi CLENZIderm M.D.(TM) acne therapeutic systems, 2007; aformulation of CLENZIderm M.D.(TM) Systems